Latest Breaking News On - Tesaro inc - Page 18 : vimarsana.com
Judge throws out suit against Tesaro board over $5 1 bln sale
reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022
forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Published: Jul 02, 2021 By Alex Keown
OcuTerra Therapeutics – David J. Tanzer was named Chief Medical Officer and Executive Vice President, Clinical and Medical Affairs for Boston-based OcuTerra. Prior to joining OcuTerra, Tanzer served as Global Executive Medical Director in the Novartis ophthalmology franchise. Before that, he served as the CMO at Abbott Medical Optics. He also led the Navy Refractive Surgery Program in San Diego, participating as principal or co-investigator in over 50 clinical studies.
Delix Therapeutics – David E. Olson, co-founder and Chief Scientific Officer of Delix Therapeutics, was an Innovator of the Year award winner at UC Davis. Olson is an assistant professor in the Department of Chemistry and Department of Biochemistry and Molecular Medicine at UC Davis. He was named an Innovator of the Year for his groundbreaking work with non-hallucinatory psychedelics that have the potential to make “measurable societal impact.” Olson and his
Several matter pinch shares of
Tesaro, Inc. (NASDAQ:TSRO) [Trend Analysis], as shares plunging -0.72% to $185.56 with a share volume of 149477. Tesaro (TSRO) confirmed that the CHMP rendered a positive opinion for the marketing authorization application for VARUBY for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.
“Following ‘s positive CHMP opinion, and subject to final approval and completion of pricing and reimbursement discussions, TESARO plans to launch VARUBY in Europe beginning in the first half of 2017, on a country-by-country basis. Our international organization now spans 17 European countries and is well prepared to make this treatment accessible in each country as soon as possible.” The stock is going forward its 52-week low with 413.87% and moving down from its 52-week high price with -3.83%. To have technical analysis views, liquidity ratio of a company was calculated 11.60 as eval
ADVERTISEMENT
ADVERTISEMENT
Tesaro Directors Slam Innuendo In Del. Suit Over $5.1B Sale
Law360 (May 11, 2021, 8:59 PM EDT) A class of Tesaro stockholders seeking damages for an allegedly underpriced $5.1 billion sale of the cancer drugmaker in 2018 came to Chancery Court with a suit heavy on innuendo and speculation but short of facts, an attorney for the company s board told a Delaware vice chancellor Tuesday.
Timothy R. Farrell of Ropes & Gray LLP, counsel for Tesaro Inc. s directors and officers, told Vice Chancellor Morgan T. Zurn during a teleconferenced dismissal argument that GlaxoSmithKline acquired the company for 182% of its unaffected stock price in a deal approved by 83% of stockholders.
vimarsana © 2020. All Rights Reserved.